TAVI Reimbursement Expansion for Low- and Inter...

By João L. Carapinha

March 19, 2026

The TAVI reimbursement expansion announced by Zorginstituut Nederland on March 10, 2026, includes...
PRIME Scheme Evaluation: Insights from Enhanced Development Tools Pilot
EU Approves Imfinzi Gastric Cancer Treatment as Perioperative Immunotherapy
Europe Life Sciences Competitiveness: Addressing Decline and Unlocking Potential
Bridging Analyses: The Role of Cost Per Event Avoided in Evaluating GLP-1 Ago...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...